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Recent studies suggest that the second extracellular loop (o2
loop) of bovine rhodopsin and other class I G protein-coupled
receptors (GPCRs) targetedbybiogenic amine ligands folds deeply
into the transmembrane receptor core where the binding of cis-
retinal and biogenic amine ligands is known to occur. In the past,
the potential role of the o2 loop in agonist-dependent activation of
biogenic amine GPCRs has not been studied systematically. To
address this issue, we used theM3muscarinic acetylcholine recep-
tor (M3R), a prototypic class I GPCR, as a model system. Specifi-
cally, we subjected the o2 loop of theM3R to randommutagenesis
and subsequently applied a novel yeast genetic screen to identity
single amino acid substitutions that interferedwithM3R function.
This screen led to the recovery of about 20mutantM3Rs contain-
ing single amino acid changes in the o2 loop that were inactive in
yeast. In contrast, application of the same strategy to the extracel-
lular N-terminal domain of theM3R did not yield any single point
mutations that disruptedM3R function. Pharmacological charac-
terization of many of the recovered mutant M3Rs in mammalian
cells, complemented by site-directed mutagenesis studies, indi-
cated that the presence of several o2 loop residues is important for
efficient agonist-induced M3R activation. Besides the highly con-
servedCys220 residue, Gln207, Gly211, Arg213, Gly218, Ile222, Phe224,
Leu225, andPro228were found tobeofparticular functional impor-
tance. In general, mutational modification of these residues had
little effect on agonist binding affinities.Our findings are therefore
consistent with a model in which multiple o2 loop residues are
involved in stabilizing the active state of the M3R. Given the high
degree of structural homology found among all biogenic amine
GPCRs, our findings should be of considerable general relevance.
G protein-coupled receptors (GPCRs)3 represent the largest
class of cell surface receptors found in nature (1–6). GPCR-
mediated signaling pathways regulate the activity of an extraor-
dinarily large number of physiological functions. GPCRs are
activated by the binding of different structural classes of extra-
cellular ligands, including neurotransmitters, hormones, and
sensory stimuli (1–6). All GPCRs are predicted to share a com-
mon molecular structure consisting of seven transmembrane
helical domains (TM I–VII) connected by three intracellular
and three extracellular loops (1–3).
Based on sequence similarity, the mammalian GPCRs can be
subclassified into several major subfamilies (1–6). Family I rep-
resents by far the largest subgroup of GPCRs, consisting of
about 700 different members in human (4). Because the mem-
bers of this receptor family share considerable sequence
homologywith rhodopsin, the class IGPCRs are also referred to
as rhodopsin-like GPCRs. Most small ligands acting on class I
GPCRs, including rhodopsin and the classic biogenic amine
ligands such as acetylcholine, dopamine, norepinephrine, or
serotonin, are predicted to bind to their target receptors within
a cavity formed by the ring-like arrangement of the seven TM
helices (7–10). Specifically, these ligands are thought to interact
with amino acids located within the exofacial segments of TM
III, V, VI, and VII (7–10).
Interestingly, the x-ray structure of bovine rhodopsin sug-
gests that residues contained in the second extracellular loop
(o2 loop)may also play a role in ligand (cis-retinal) binding, and,
perhaps, rhodopsin activation (11). The x-ray structure clearly
shows that a portion of the o2 loop, the so-called 4 strand,
folds deeply into the center of the TM receptor core, allowing
several o2 loop residues to contact the cis-retinal ligand (11). In
contrast, the twoother extracellular loops run along the periph-
ery of the receptor molecule. The proper orientation of the o2
loop is maintained by a disulfide bond that is highly conserved
among class IGPCRs (1, 2, 11).One of theCys residues involved
in this disulfide bond is located in the center of the o2 loop
(corresponding to Cys220 in Fig. 1), and the other one is located
at the extracellular end of TM III (corresponding to Cys140 in
Fig. 1). Numerous studies have shown that the presence of this
conserved disulfide bond is critical for proper receptor folding
and cell surface localization (see Ref. 12 and references therein).
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Interestingly, biochemical analysis of theD2 dopamine receptor
by the substituted-cysteine accessibility method strongly sug-
gests that the o2 loop of biogenic amine GPCRs may adopt a
structure similar to that observed with bovine rhodopsin (13).
At present, little is known about the roles of the extracellular
receptor domains in the function of class I GPCRs that are
activated by small diffusible ligands. In the case of the musca-
rinic receptors, the extracellular domains, including the o2
loop, have been shown to play important roles in the binding of
certain snake toxins that prevent receptor activation by classic
muscarinic agonists (14–16). Moreover, mutagenesis studies
carried out with differentmuscarinic receptor subtypes suggest
that residues located within the o2 loop and other extracellular
domains make critical contacts with allosteric muscarinic
ligands (17). However, it remains unclear whether the o2 loop,
or residues contained within other extracellular receptor
regions, contributes to the binding of classic muscarinic ago-
nists and/or agonist-induced receptor activation.
To address this issue, we have used the M3 muscarinic ace-
tylcholine receptor (M3R), a prototypic class I GPCR that is
preferentially coupled to G proteins of the Gq family (8), as a
model system. In previous studies, we identified many residues
located within different TM helices and on the intracellular
receptor surface that are critical for various aspects of M3R
function (8). Because of the critical role of the o2 loop in ligand
recognition in rhodopsin, we decided to investigate whether
efficientM3R activation depends on the presence of specific o2
loop residues (besides the conservedCys220 residue). In general,
classic mutagenesis techniques are limited by the relatively
small number of mutations that can be generated and analyzed
in one particular study. We therefore decided to use random
mutagenesis techniques to generate a large library of mutant
M3Rs containing point mutations in the o2 loop (“o2 loop
library”). To select for point mutations that interfere withM3R
function, we employed a novel yeast genetic screen that
allows the recovery of yeast clones expressing functionally
inactive M3Rs (18). In contrast to this approach, previous
yeast genetic screens that were used to study GPCR function
were all designed to recover functionally active mutants
GPCRs (19–26).
As is the case for the o2 loop, the potential functional roles of
theN-terminal extracellular domain (N-term) has also not been
studied systematically in class I GPCRs. In bovine rhodopsin,
the N-term region, together with the o2 loop, forms a compact
structure at the entrance of the TM-binding core (11). We
therefore also generated an “N-term library” of randomly
mutagenized M3Rs and subjected this library to the same
genetic screen as described above for the o2 loop library.
Following the initial yeast screen, all receptors harboring
single inactivating point mutations were expressed and char-
acterized in more detail in transfected mammalian (COS-7)
cells. In addition, we also generated and analyzed (in trans-
fected COS-cells) a series of mutant M3Rs in which specific
amino acids in the o2 loop were replaced with alanine (Ala).
These Ala substitutions were introduced at sites predicted to
be critical for efficient M3R activation, based on the initial
characterization of the mutant M3Rs recovered in the yeast
genetic screen.
By using this spectrum of complementary experimental
approaches, we were able to identify several o2 loop residues
that are critical for efficient agonist-induced M3R activation
but do not seem to play an important role in the binding of
carbachol, a classic muscarinic agonist. The majority of these
residues is conserved among all five muscarinic receptor sub-
types (M1–M5). To our knowledge, this study represents by far
themost comprehensive analysis of the functional role of the o2
loop of a class I GPCR activated by a small diffusible ligand. The
experimental approach described here should be generally
applicable to all GPCRs that can be expressed in yeast in a func-
tional form.
EXPERIMENTAL PROCEDURES
Materials—Carbamylcholine chloride (carbachol), atropine
sulfate, and 3-amino-1,2,4-triazole were obtained from Sigma.
N-[3H]Methylscopolamine ([3H]NMS; 79–83 Ci/mmol) was
fromPerkinElmer Life Sciences.Media formammalian cell cul-
ture were from Invitrogen. Yeast media components were pur-
chased fromQbiogene. All enzymes used formolecular cloning
were from New England Biolabs.
Properties of the Yeast Strain Used and Yeast Growth and
Transformation—The haploid yeast (Saccharomyces cerevisiae)
strain MPY578q5 (MATa GPA1 far1::LYS2 fus1::FUS1-HIS3
sst2::SST2-G418r ste2::LEU2 fus2::FUS2-CAN1 ura3 lys2 ade2
his3 leu2 trp1 can1) was used as a host for the expression of all
M3R constructs (27). This strain harbors a mutant version of
the endogenousGPA1 gene coding for amodified version of the
Gpa1p G protein  subunit in which the last 5 amino acids of
Gpa1p were replaced with the corresponding sequence derived
from mammalian Gq. Moreover, this strain lacks functional
FAR1, SST2, and STE2 genes and contains the pheromone-sen-
sitive FUS1-HIS and FUS2-CAN1 reporter genes (Fig. 2). Yeast
cells were grown and transformed with plasmid DNA as
described previously (24, 27).
Generation of Yeast Libraries Expressing Randomly
Mutagenized M3Rs—For yeast expression studies, all muta-
tions were introduced into a modified version of the rat M3R
lacking the central portion of the i3 loop (Ala274–Lys469) and
containing an N-terminal hemagglutinin (HA) and a C-termi-
nal enhanced green fluorescent protein (EGFP) tag (Fig. 1) (18).
For the sake of simplicity, this receptor is referred to as
M3R(i3) throughout. The M3R(i3) coding sequence was
inserted into the p416GPD yeast expression plasmid as
described previously (27), yielding plasmid p416GPD-
M3R(i3). TheM3R(i3) sequence coding for the extracellular
N-terminal domain of the receptor (Thr2–Gln66, Fig. 1) was
subjected to PCR-based random mutagenesis to generate, on
average, one nucleotide misincorporation per receptor con-
struct (28). PCRs were carried out in 50l in the presence of 10
mMTris-HCl (pH8.3), 50mMKCl, 7mMMgCl2, 0.5mMMnCl2,
0.001% (w/v) gelatin, 1 mM dCTP, 1 mM dTTP, 0.2 mM dATP,
0.2 mM dGTP, 0.5 M of each primer, 50 ng of template DNA
(p416GPD-M3R(i3)), and 3units ofAmpliTaqDNApolymer-
ase (Applied Biosystems). PCR cycling conditions were as fol-
lows: 35 cycles at 94 °C for 60 s, 55 °C for 60 s, and 72 °C for 60 s.
The following PCR primers were used: sense, 5-TTA GTT
TCG ACG GAT TCT AGA ACT AGA AAA ATG TAC CCC
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TAC GAC GTC CCC GAC TAC GCC-3; antisense, 5-GAT
GGT CAC CAA TGC CAG GAA GCC AGT TAA GAA GGC
AATGAAGACCAC-3. The size of the final PCR product was
306 bp.
To generate a library of yeast clones expressingmutantM3Rs
containing pointmutations within the extracellular N-terminal
domain, we used a gap-repair protocol (27, 29). The 306-bp
PCR fragment (4 g) generated under error-prone PCR con-
ditions (see previous paragraph) was cotransformed into
MPY578q5 with the p416GPD-M3R(i3) yeast expression
plasmid (10g) that had been linearizedwithAatIIwithin the
region corresponding to the 306-bp PCR fragment. This proce-
dure resulted in a yeast expression library consisting of 1 
105 primary transformants (colonies that were able to grow on
plates lacking uracil).
Similarly, the o2 loop of the M3R(i3) was also subjected to
random mutagenesis. In this case, we used an oligonucleotide
that had been synthesized chemically under error-prone con-
ditions (30). The following sense primer coding for M3R resi-
dues Pro201 to Phe232 was synthesized by Genemed Synthesis
Inc. (San Francisco, CA): 5-CCT GCC ATC TTG TTC TGG
CAA TAC TTT GTA GGG AAG AGA ACT GTG CCC CCA
GGA GAA TGT TTC ATT CAG TTT CTG AGT GAG CCC
ACCATCACCTTC-3. The underlined sequence, which cor-
responds to o2 loop residues Phe205 to Pro228 (Fig. 1), was syn-
thesized under conditions that led to one nucleotide misincor-
poration (on average) per molecule (the underlined sequence
was doped with 1% non-wild-type nucleotides). A standard
PCR was then carried out using this mutagenic sense primer
together with an antisense primer (5-GGC GGC CTT CTT
CTC CTT GAT GAG-3; corresponding to residues Leu482 to
Ala489) to generate a PCR product of 246 bp. This 246-bp PCR
fragmentwas then used as a template for a second roundof PCR
using a sense primer that overlapped with the first 12 nucleo-
tides (underlined) of the mutagenic oligonucleotide (5-ATG
ATT GGT CTG GCT TGG GTC ATC TCC TTT GTC CTA
TGGGCTCCTGCCATCTTG-3). The antisense primer was
identical to the one used of the first PCR. The resulting 288-bp
PCR product (3 g) was cotransformed intoMPY578q5 with
the p416GPD-M3R(i3) yeast expression plasmid (12 g)
linearized with BstXI within the region corresponding to the
288-bp PCR fragment. This gap repair protocol (29) yielded a
yeast expression library consisting of1 105 primary trans-
formants (colonies that were able to grow on plates lacking
uracil).
Yeast Genetic Screen to Identify Functionally InactiveMutant
M3Rs—As described in the previous paragraph, the primary
yeast transformants were grown on plates containing uracil-
deficient synthetic complete (SC) medium to select for Ura
(plasmid-containing) transformants (plating density,2,000–
8,000 clones/150-mm plate). After incubating the plates for 2
days at 30 °C, the resulting colonies were transferred, via repli-
ca-plating, onto plates containing SCmedium that lacked both
uracil and arginine but contained 1 mM carbachol and 150
g/ml canavanine. In addition, arginine was omitted from the
medium because it can compete with canavanine for uptake by
the Can1p transporter. A total of 1  105 yeast clones (pri-
mary transformants) was screened for each of the two librar-
ies. Yeast clones that survived the carbachol/canavanine
selection step were first studied for GFP fluorescence using
the FlexStation (excitation wavelength, 485 nm; emission
wavelength, 525 nm; Molecular Devices) and epi-fluorescence
microscopy (AX10, Carl Zeiss). To quantitate GFP fluores-
cence via the use of the FlexStation, yeast cell suspensions were
analyzed in a 100- l volume using a 96-wellplate format (Fig.
3). Yeast clones that failed to display pronounced GFP fluores-
cence were eliminated at this step. The remaining yeast clones
were subjected to a second round of screening. Specifically,
plasmids were isolated from these clones, amplified in Esche-
richia coli (DH5), and retransformed into MPY578q5 to con-
firm the plasmid linkage of the observed growth phenotype.
Expression of Mutant M3Rs Recovered in the Yeast Genetic
Screen in Mammalian Cells—Most inactivating point muta-
tions recovered in the yeast genetic screen were subcloned into
a mammalian expression vector (pCD-PS) coding for the full-
length M3R containing an N-terminal HA and a C-terminal
EGFP tag (18). For the sake of simplicity, this receptor is
referred to as “WT” M3R throughout. All resulting receptor
constructs were transiently expressed in COS-7 cells (24). For
receptor binding studies, COS-7 cells were transfected in
100-mm dishes, as described previously (24). For functional
studies, COS-7 cells were seeded into 96-well plates (1.5 104
cells/well; catalog number 3603, Corning Glass) 24 h before
transfection. Cells were transfected with 100 ng of plasmid
DNA per well, using the Lipofectamine Plus kit (Invitrogen).
Calciummobilization assayswere carried out 2 days after trans-
fections (see below).
Site-directedMutagenesis—To introduceAla substitutions at
specific positions of the o2 loop of the “WT”M3R, we used the
QuikChange site-directedmutagenesis kit fromStratagene, fol-
lowing the manufacturer’s instructions. To generate a mutant
“WT” M3R that lacked most of the extracellular N-terminal
domain (M3R(Nterm); amino acids Thr2–His62 were
deleted), we used standard PCR-basedmutagenesis techniques.
The identity of all receptor constructs was verified by DNA
sequencing.
Radioligand Binding Studies—Transfected COS-7 cells were
harvested 72 h after transfection, and cell membranes were
prepared as described in detail previously (24). Radioligand
binding assays were carried out in a 1-ml volume using mem-
branes prepared from transfected COS-7 cells suspended in a
buffer containing 25 mM sodium phosphate and 5 mM MgCl2
(pH 7.4). Samples were incubated for 3 h at room temperature
(22 °C) in the presence of the muscarinic antagonist [3H]NMS.
[3H]NMS saturation binding and [3H]NMS/carbachol inhibi-
tion binding studies were carried out essentially as described
(24). Nonspecific binding was assessed as binding remaining in
the presence of 10 M atropine. Reactions were terminated by
rapidly filtration over GF/C Brandel filters, and the amount of
bound radioactivity was determined by liquid scintillation
spectrometry. Binding data were analyzed using the nonlinear
curve-fitting program Prism 4.0b (GraphPad).
Functional Assays (FLIPR)—Functional assays were carried
out with receptor-expressing COS-7 cells 2 days after transfec-
tion. Specifically, we used FLIPR technology (Molecular
Devices) to measure carbachol-mediated increases in intracel-
M3Muscarinic Receptor Function
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lular calcium levels. COS-7 cells grown in 96-well plates were
washed once with 200 l of Hanks’ balanced salt solution con-
taining 20 mM HEPES (pH 7.4) and then incubated for 1 h at
37 °C with 30 l of loading dye (FLIPR Calcium 3 assay kit,
Molecular Devices), supplemented with 5 mM probenecid to
increase dye retention. Subsequently, increasing concentra-
tions of carbachol were added, and changes in cell fluorescence
weremeasured at room temperature via FLIPR (FLIPRTETRA,
Molecular Devices; excitation wavelength, 470–495 nm; emis-
sion wavelength, 515–575 nm), as described previously (31).
For each carbachol concentration, increases in intracellular cal-
cium levels were measured as peak fluorescence activity (FI)
minus basal FI prior to the addition of carbachol. Carbachol
Emax and EC50 values were obtained from concentration-re-
sponse curves using GraphPad Prism (version 4.0b; GraphPad
Software). To normalize the functional data obtained with the
different mutant M3R constructs, “WT” M3R-expressing cells
were included in each individual experiment. In all experi-
ments, the Emax value obtained with “WT” M3R-expressing
cells was set equal to 100%. Assays were carried out in
quadruplicate.
Receptor Modeling—A three-dimensional model of the TM
core of the rat M3R, including the various loop regions and
helix 8, was built using homology modeling based on the x-ray
structure of the inactive state of bovine rhodopsin (11), as
described previously (48). Tomodel the o2 loop of theM3R, the
two -sheet domains (3 and 4) of the o2 loop of bovine rho-
dopsin were first aligned with the corresponding M3R
sequences, followed by the addition or deletion of specific o2
loop segments.
Data Analysis—Binding and functional parameters were
estimated using Prism, version 4.0b (GraphPad Software). Car-
bachol IC50 values determined in [3H]NMS/carbachol inhibi-
tion binding studies were converted to Ki values by using the
Cheng-Prusoff equation (32).
RESULTS
Identification of Single Point Mutations in the o2 Loop That
AbolishM3R Function in Yeast—In this study, we used random
mutagenesis to introduce pointmutations into the extracellular
N-terminal region (N-term) and the o2 loop of the ratM3R. All
mutations were introduced into a modified version of the M3R
that lacked the central portion of the third intracellular loop (i3
loop; Ala274–Lys469) and contained an N-terminal HA and a
C-terminal EGFP tag (Fig. 1). For the sake of simplicity, this
construct is referred to as M3R(i3) throughout. We recently
demonstrated that the N- and C-terminal tags do not interfere
with M3R function in yeast and mammalian cells (18). More-
over, the deletion of residues Ala274–Lys469 leads to a dramatic
improvement of M3R expression levels in yeast (27), but it has
no significant effect on the ligand binding and G protein-cou-
pling properties of the M3R (12, 33, 34).
FIGURE 1.Amino acid sequence of the ratM3R highlighting residues thatwere targeted in this study. For expression studies in yeast, all mutations were
introduced into a modified version of the rat M3R (M3R(i3)) lacking the central portion of the i3 loop (Ala274–Lys469) and containing an HA tag (amino acid
sequence, YPYDVPDYA) at theN terminus and an EGFP tag at theC terminus, respectively (18). The extracellular N-terminal region (Thr2–Gln66) and the o2 loop
(Phe205–Pro228) were subjected to random mutagenesis. The brackets shown correspond to the 3 and 5 ends of the PCR products that were produced to
generate the two yeast expression libraries (see “Experimental Procedures” for details). Amino acid numbers refer to positions in the full-length rat M3R
sequence (46).
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The M3R(i3) construct and all M3R(i3)-derived mutant
receptors were expressed in theMPY578q5 yeast (S. cerevisiae)
strain (27). Besides containing several other genetic modifica-
tions (see Fig. 2 and “Experimental Procedures” for details), this
strain expresses a chimeric yeast Gpa1p/mammalian Gq G
protein  subunit in which the last five amino acids of Gpa1p
were replaced with the corresponding mammalian Gq resi-
dues.When expressed in theMPY578q5 strain, theM3R(i3) is
able to activate this chimeric G protein with high efficiency,
leading to the stimulation of the yeast pheromone pathway
which in turn triggers the activation of the pheromone-sensi-
tive FUS2-CAN1 receptor gene (18, 27) (Fig. 2).
We subjected the N-term region (Thr2–Gln66) and the o2
loop (Phe205–Pro228) of theM3R(i3) to PCR/oligonucleotide-
based randommutagenesis (see “Experimental Procedures” for
details). PCR products containing nucleotide misincorpora-
tions were cotransformed into MPY578q5 with a gapped (lin-
earized) version of the M3R(i3)-p416GPD yeast expression
plasmid. This procedure, also referred to as the gap-repair
method (29), led to the regeneration of circular plasmids,
because of the high recombination activity of yeast.
To generate a large number of mutant receptors containing
single amino acid substitutions and to reduce the likelihood of
generating receptor constructs harboring multiple amino acid
changes, we chose mutagenic con-
ditions that led to a rather low
mutagenesis rate (0.5–1 nucleotide
changes per receptor construct). To
assess the quality of the N-term and
o2 loop yeast libraries, we recovered
and sequenced plasmids from 60
randomly picked yeast colonies
(primary transformants; 30 colo-
nies from each library) growing on
plates containing SC medium
lacking uracil (SC-Ura medium;
note that the p416GPD plasmid
contains the URA selection
marker). This analysis showed that
the nucleotide misincorporation
rate for the N-term library was
0.7 nucleotides per receptor con-
struct. A similar mutagenesis rate
was found for the o2 loop library
(0.9 nucleotides per receptor con-
struct). We noted that the nucleo-
tide changes were randomly distrib-
uted throughout the two targeted
receptor sequences.
Altogether, 89 amino acids
(Thr2–Gln66 and Phe205–Pro228),
corresponding to 267 nucleotides,
were subjected to randommutagen-
esis. The total number of possible
single nucleotide changes is 801
(3  267). Sequencing studies
showed that 20% of all primary
yeast transformants harbored M3R
plasmids containing single nucleotide changes. Assuming that
the point mutations occurred in a completely random fashion,
4,005 yeast clones should provide a 1 coverage of all possible
single nucleotide substitutions (100/20  801). As indicated
below, we screened a total of2 105 yeast clones. This num-
ber represents an50-fold excess over the number required to
achieve complete coverage of all possible single nucleotide sub-
stitutions. It is therefore highly likely that the number of yeast
clones screened in this study included all possible single nucle-
otide substitutions.
Each yeast library consisted of about 1 105 primary trans-
formants giving rise to colonies on SC-Ura medium (plating
density, 2,000–8,000 colonies/150-mm plate). The primary
transformants were replica-plated onto SCmedium containing
carbachol (1mM) and the cytotoxin canavanine (150g/ml) but
lacking uracil and arginine (SC-Arg-Ura medium). Arginine
was omitted from the medium because it competes with cana-
vanine for uptake by the Can1p transporter. Under these selec-
tion conditions, the binding of carbachol to a functional receptor
leads to theactivationof theFUS2-CAN1 receptor gene, triggering
the synthesis and membrane insertion of the Can1p transporter
protein through which the cytotoxin canavanine can enter the
yeast cytoplasm (Figs. 2 and 3). As a result, yeast cells expressing
functional M3Rs are unable to grow in the presence of carba-
FIGURE 2. Summary of the yeast pathway linking carbachol-mediated M3R activation to cell death. All
M3R constructs were expressed in the MPY578q5 yeast (S. cerevisiae) strain. This strain has been subjected to
the following geneticmanipulations (27, 47) allowing the recovery of inactivemutantM3Rs under appropriate
selection conditions (see below) as follows. 1) The endogenous yeast pheromone GPCR gene (STE2) has been
deleted. 2) The endogenous G protein subunit (Gpa1p) has been substitutedwith a chimeric yeast/mamma-
lian G protein in which the last five amino acids of Gpa1p were replaced with the corresponding residues
present inmammalianGq. 3) The SST2gene ,which codes for an RGSprotein, has beendeleted to increase the
lifetime of the activated G protein. 4) The FAR1 gene has been deleted to permit yeast growth despite activa-
tion of the MAPK pathway. In this strain, carbachol binding to functional M3Rs leads to the activation of the
yeast MAPK/pheromone pathway. Stimulation of this pathway eventually leads to activation of the phero-
mone-sensitive FUS2-CAN1 reporter gene and the expression of Can1 permease that acts as a transporter
protein for the cytotoxic agent canavanine. Thus, yeast clones that express functionalM3Rswill not grow in the
simultaneouspresenceof carbachol andcanavanine.However, under the sameexperimental conditions, yeast
clones containing functionally inactivemutantM3Rswill give rise to colonies fromwhich plasmidDNAs canbe
isolated and sequenced.
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chol and canavanine. However, under the same experimental
conditions, yeast clones harboring functionally inactivemutant
M3Rs are able to grow (Figs. 2 and 3).
Altogether, we picked 1,506
(N-term library) and 1,727 yeast
colonies (o2 loop library), respec-
tively, that showed robust growth in
the presence of carbachol and cana-
vanine. Because the GFP tag was
fused to the C terminus of theM3R,
mutant receptors containing non-
sense mutations (premature stop
codons) were predicted to give no
GFP signal. Similarly, cells harbor-
ing mutant M3Rs that were
expressed at low levels in yeast were
expected to show only weak GFP
fluorescence. To select for full-
length mutant receptors that were
expressed at high levels in yeast, we
therefore examined suspensions of
the recovered yeast clones for GFP
fluorescence, using a 96-well plate
format (see “Experimental Proce-
dures” for details; Fig. 3). Under
these experimental conditions, the
majority of the analyzed yeast clones showed none or only weak
GFP fluorescence. Most likely, these clones contained trun-
cated receptors, either due to nonsense or frameshift muta-
tions, or full-length mutant receptors that were unstable in
yeast. However, 372 (10%) of the analyzed yeast clones gave a
robust fluorescence signal. These clones were then subjected to
a second round of screening to confirm the plasmid depend-
ence of the growth phenotype. The plasmids contained in the
yeast clones that passed this second round of screening (95%)
were sequenced.
Specifically, we sequenced 230 plasmids originating from the
o2 loop library. More than half of these plasmids contained
multiple point mutations; the encoded mutant receptors were
not analyzed further. However, we also identified 77 plasmids
coding for mutant M3Rs containing single amino acid changes
(Table 1). Most of these single amino acid substitutions were
recovered twoormore times (Table 1), suggesting that the yeast
screen was performed at or near saturating conditions. In sev-
eral cases, specific o2 loop residues (Arg213, Cys220, Gln223, and
Phe224) were found to be replaced by three or more different
amino acids (Table 1), indicative of the potential functional
importance of these amino acids. We also identified several
inactivating point mutations in TM IV and TM V, which are
connected by the o2 loop (W192C, S195F, W199C, W199R,
P201L, F239L, and P242S; Table 1). Although the TM regions
were not targeted by randommutagenesis, it is likely that these
mutations arose because of PCR errors during the generation of
the PCR fragment used for constructing the o2 loop yeast
expression library (see “Experimental Procedures” for details).
The W192C, P201L, and P242S point mutations involve three
residues that are highly conserved among class I GPCRs (posi-
tions 4.50, 4.59, and 5.50 according to the Ballesteros/Wein-
stein amino acid nomenclature of GPCRs see Ref. 35). The crit-
ical functional roles of these amino acids have been
documented in a large number of mutagenesis studies, con-
FIGURE3.Summaryof thestrategyusedto identifyandcharacterize full-lengthmutantM3Rscontaining
inactivating point mutations. We generated PCR fragments in which the sequences corresponding to the
N-terminal region and the o2 loop of the M3R were subjected to random mutagenesis (see “Experimental
Procedures” for details). All mutations were introduced into the M3R(i3)-p416GPD yeast expression plasmid
(Ura selection), taking advantage of the gap-repair method (29). The mutant M3R expression libraries were
createdusing theMPY578q5 yeast strain (see Fig. 2). Theprimary yeast transformantswere replica-plated onto
medium that lacked uracil and arginine (SC-Ura-Arg) but contained the cytotoxin canavanine (150g/ml) and
the muscarinic agonist carbachol (1 mM). Under these conditions, only those yeast clones that contained
inactive mutant M3Rs gave rise to colonies. To ensure that the yeast clones that survived the carbachol/
canavanine selection procedure contained full-length receptors that were stable in yeast, all surviving clones
were studied forGFP fluorescence. Yeast clones that didnot yield a robust fluorescence signalwere eliminated.
Yeast clones displaying robust GFP fluorescence were subjected to a second round of screening. Specifically,
plasmids were isolated from these yeast clones, amplified in E. coli (DH5), and retransformed intoMPY578q5
to confirm that the observed growth phenotype was indeed plasmid-dependent.
TABLE 1
Single point mutations that disrupted M3R function in yeast
The indicated point mutations disrupted M3R function in yeast strain MPY578q5.
Plasmids coding for the indicated mutant receptors were isolated from yeast clones
that were able to grow on plates containing carbachol (1 mM) and canavanine (150
g/ml). All mutations were introduced into the M3R(i3) construct, a modified
version of the rat M3R that lacked amino acids Ala274–Lys469, and contained an
N-terminal HA and a C-terminal EGFP tag (Fig. 1). Yeast clones expressing the
indicated mutant receptors showed pronounced GFP fluorescence, indicating that
the various point mutations did not destabilize the M3R(i3) protein. For details,
see “Experimental Procedures.”
Inactivating point
mutation
No. of
recovered yeast
clones
Localization
W192C 3 TM IV
S195F 2 TM IV
W199C 2 TM IV
W199R 4 TM IV
P201L 1 TM IV
F205V 1 TM IV/o2 junction
Q207L 4 o2
G211W 2 o2
R213T 4 o2
R213I 3 o2
R213S 4 o2
R213G 2 o2
G218V 1 o2
C220S 6 o2
C220W 3 o2
C220F 4 o2
C220G 4 o2
C220R 2 o2
I222T 3 o2
Q223K 3 o2
Q223L 1 o2
Q223H 2 o2
F224Y 1 o2
F224S 2 o2
F224V 2 o2
L225P 3 o2
P228L 3 o2
F239L 3 TM V
P242S 2 TM V
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firming the usefulness of the yeast screening strategy used in
this study to identify residues critical for M3R function.
We also sequenced 124 plasmids originating from yeast
clones contained in the N-term (Thr2–Gln66) library that sur-
vived the carbachol/canavanine andGFP screening procedures.
Most of these plasmids contained multiple point mutations.
We did not recover any plasmids coding for receptors harbor-
ing single amino acid changes.
Analysis of Inactive Mutant M3Rs Recovered in the Yeast
Genetic Screen inMammalian Cells—Above, we described sin-
gle point mutations in the o2 loop that abolished M3R activity
in yeast. We next wanted to explore whether these mutations
had similar effects in a mammalian expression system. Toward
this goal, we introduced representative point mutations into a
mammalian expression plasmid (pCD) coding for the full-
length M3R containing an N-terminal HA and a C-terminal
EGFP tag. For the sake of simplicity, this receptor construct is
referred to as “WT” M3R throughout. We recently reported
that the N- and C-terminal tags have little effect on the ligand
binding and functional properties of the M3R (18).
The “WT” M3R and all “WT” M3R-derived mutant recep-
tors were transiently expressed in COS-7 cells and character-
ized in radioligand binding and functional studies (Table 2). In
a previous study, we demonstrated that Cys220 plays a critical
role in properM3R folding (12). This Cys residue is highly con-
served among class I GPCRs and is predicted to form a disulfide
bond with a conserved Cys residue present at the extracellular
end ofTMIII (Cys140 in theM3R; Fig. 1) (11, 36). Because of this
earlier report (12), we did not analyze the recovered Cys220
mutant receptors any further (Table 1).
We first studied the ability of the “WT” M3R and the differ-
ent mutant receptors to bind the muscarinic antagonist
[3H]NMS. With the exception of the Q207L construct, all ana-
lyzed receptors containing single pointmutations in the o2 loop
retained the ability to bind [3H]NMSwith high affinity (range of
Kd values, 118–566 pM; see Table 2). TheQ207Lmutant recep-
tor bound [3H]NMS with17-fold lower affinity, as compared
with the “WT”M3R (Table 2). All mutant receptors displayed a
reduction inBmax values (maximumnumber of [3H]NMS bind-
ing sites), ranging from 28.4 to 65.5% of the corresponding
“WT” M3R value (100%; Table 2). [3H]NMS/carbachol inhibi-
tion binding studies showed that most analyzed mutant recep-
tors retained the ability to bind the muscarinic agonist, carba-
chol, with high affinities that differed from the corresponding
“WT” M3R value by less than 3-fold (Table 2). However, the
I222T, Q223K, F224Y, and L225P mutant receptors showed
5.2-, 5.4-, 24-, and 31-fold, respectively, lower carbachol affini-
ties than the “WT” M3R (Table 2).
To examine whether the different mutant receptors were
able to couple to G proteins in transfected COS-7 cells, we
measured carbachol-mediated increases in intracellular cal-
cium levels using FLIPR technology. As shown in Table 2, all
analyzed mutant receptors retained the ability to trigger
carbachol-dependent elevations in intracellular calcium levels.
However, with the exception of the Q223K mutant receptor
that showed unchanged functional efficacy, all mutant recep-
tors showed a significant reduction in maximum functional
responses (Emax values), as compared with the “WT” M3R
(Table 2). Interestingly, all analyzedmutant receptors showed a
pronounced reduction in carbachol potencies (increases in
EC50 values; Table 2). Althoughmostmutant receptors showed
8–38-fold lower carbachol potencies than the “WT” M3R, the
Q207L and the L225P constructs displayed evenmore dramatic
decreases in carbachol potencies (600- and 2,530-fold, respec-
tively; Table 2).
To investigate to which extent the observed decreases in
receptor expression levels (Bmax values) contributed to the
functional deficits displayed by the analyzed mutant receptors,
we systematically reduced the expression levels of the “WT”
M3R and then studied carbachol-mediated calcium responses
at different “WT” M3R densities. These studies showed that
stepwise reduction of “WT”M3R expression levels led to a pro-
gressive decrease in carbachol Emax values (Table 3). However,
even a drastic reduction in Bmax values by 80% still yielded an
Emax value of 48.8% (Table 3, bottom line). In contrast, the step-
wise reduction of “WT” M3R expression levels had little effect
on carbachol EC50 values (Table 3). Themaximum reduction in
carbachol potency that we observed was only 2.2-fold (Table 3,
TABLE 2
Characterization of mutant M3Rs recovered in the yeast screen in mammalian cells
The indicated mutant M3Rs were transiently expressed in COS-7 cells. All point mutations were introduced into the “WT” M3R (full-length rat M3R containing an
N-terminal HA and a C-terminal EGFP tag). The M3R(Nterm) construct lacks the extracellular N-terminal portion of the M3R (Thr2–His62; see Fig. 1). The Bmax value
for the “WT”M3Rwas 4.2 0.7 pmol/mg protein, as determined in 3HNMS saturation binding studies. Carbachol-mediated increases in intracellular calcium levels were
determined via FLIPR, as described under “Experimental Procedures.” Data are given as means S.E. of three independent experiments.
Receptor Ligand binding studies Functional studies
3HNMS Kd Carbachol Ki 3HNMS Bmax Carbachol EC50 Carbachol Emax
pM M % nM %
“WT” M3R 106 12 17.2 1.8 100 31.4 7.3 100
Q207L 1,780 44 42.4 6.7 40.2 5.6 18,810 976 60.2 12.3
G211W 184 15 20.3 3.8 28.4 2.6 562 38 71.3 9.3
R213T 488 21 37.2 1.5 35.2 3.4 845 26 82.3 9.1
R213I 475 17 31.6 4.2 30.4 3.5 753 35 77.8 6.2
R213S 135 14 32.1 2.3 38.1 4.8 650 18 80.3 8.3
R213G 231 11 44.5 2.9 39.2 5.6 948 23 85.0 7.4
G218V 118 14 13.2 2.8 36.8 4.2 254 19 94.2 8.0
I222T 166 18 90.2 7.8 65.5 6.3 1,070 37 71.2 7.3
Q223K 566 18 92.4 17.4 58.4 7.4 878 65 94.3 9.1
F224Y 221 15 406 24 56.4 7.5 635 12 88.2 6.6
L225P 510 23 536 25 41.3 5.4 79,390 1,370 71.1 7.6
P228L 169 16 23.4 3.7 30.4 3.5 1,200 99 66.9 8.0
M3R(Nterm) 135 16 13.0 2.8 12.2 1.3 81.4 8.4 40.6 4.5
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bottom line), indicating that under the experimental conditions
of the FLIPR assay carbachol potencies were relatively insensi-
tive to changes in receptor Bmax values. These observations
strongly suggest that the pronounced reductions in carbachol
potencies displayed by all analyzed mutant receptors are indic-
ative of impaired receptor function, rather than being caused
primarily by reduced receptor densities.
As described above, the screening of the N-term yeast
expression library failed to yield any receptors containing single
amino acid substitutions that disrupted M3R function in yeast.
This observation suggested that the extracellular N-terminal
domain may not be critical for M3R function. To address this
issue in a more direct fashion, we generated a mutant M3R,
referred to as M3R(Nterm), that lacked most of the extracel-
lular N-terminal domain (amino acids Thr-2-His-62 were
deleted) but still contained the HA epitope tag after the initiat-
ing Met codon (Fig. 1). When transiently expressed in COS-7
cells, the M3R(Nterm) construct showed [3H]NMS and car-
bachol binding affinities similar to the “WT” M3R (Table 2).
However, the M3R(Nterm) receptor showed pronounced
reductions in Bmax (by 90%) and Emax values (by 60%), as
compared with the “WT” M3R (Table 2). On the other hand,
the M3R(Nterm) construct showed only a small reduction
(2.6-fold) in carbachol potency (Table 2). When expressed at
similarly low levels (see Table 3, bottom line), the “WT” M3R
displayed carbachol EC50 and Emax values that were similar to
those observed with theM3R(Nterm) receptor. This observa-
tion strongly suggests that the extracellular N-terminal domain
of the M3R does not play an important role in the efficiency of
carbachol-mediated receptor activation.
Analysis ofMutantM3Rs Containing Ala Substitutions in the
o2 Loop in Mammalian Cells—The yeast genetic screen
described above yielded severalmutantM3Rs containing single
point mutations that showed significant functional deficits in
mammalian cells. To examine to which extent these functional
impairments were dependent on the chemical nature of the
newly introduced amino acid side chains, we generated a series
of mutant “WT” M3Rs containing single Ala substitutions at
functionally critical o2 loop positions, as predicted by the data
shown in Tables 1 and 2.We focused on seven o2 loop residues,
mutational modification of which resulted in the most pro-
duced reductions in functional carbachol potencies (Table 2).
Specifically, the following mutant M3Rs were generated and
characterized in transfected COS-7 cells: Q207A, R213A,
I222A, Q223A, F224A, L225A, and P228A. In addition, we also
included the E219A mutant receptor in this analysis. Although
the yeast genetic screen did not lead to the recovery of any
amino acid substitutions at this position, we decided to study
this mutant receptor because Glu219 is the only negatively
charged residue present in the o2 loop of theM3R. Because this
residue is situated directly adjacent to Cys220, the Glu219 side
chain is likely to be located inside the TM receptor core (11).
All Alamutant receptors showed [3H]NMS binding affinities
similar to the corresponding “WT”M3R value (Table 4).More-
over, the carbachol binding affinities of all analyzed Alamutant
receptors were either similar to the corresponding “WT” M3R
value or differed from this value by less than 5-fold (Table 4).
Except for the Q223A construct, all mutant receptors showed a
slight reduction in Bmax values (by15–30%; Table 4). In func-
tional assays, three of the analyzed mutant receptors, Q207A,
E219A, and Q223A, showed unchanged maximum functional
responses to carbachol (Emax; Table 4). The remaining mutant
receptors showed an10–20% reduction in Emax values (Table
4). Two of the analyzed mutant receptors, E219A and Q223A,
showed similar carbachol potencies as the “WT” M3R (Table
4). Interestingly, however, all remaining Ala mutant receptors
(Q207A, R213A, I222A, F224A, L225A, and P228A) displayed
TABLE 3
Effect of M3R expression levels on carbachol-mediated increases in
intracellular calcium levels in transfected COS-7 cells
To systematically reduce “WT”M3R expression levels, COS-7 cells were transiently
transfected in 100-mmdisheswith decreasing amounts of “WT”M3RplasmidDNA
(2 (	 100%), 1, 0.5, 0.25, 0.12, or 0.06g). Bmax values were determined in 3HNMS
saturation binding studies, as described under “Experimental Procedures.” Carba-
chol-mediated increases in intracellular calcium levels were measured via FLIPR
(for details, see “Experimental Procedures”). Data are given as means S.E. of three
independent experiments.
“WT” M3Ra expression level (Bmax) Carbachol EC50 Carbachol Emax
% nM %
100 31.4 7.3 100%
89 34.4 5.3 98.0 4.5
65 43.4 7.2 90.5 6.6
46 38.8 3.9 75.4 6.5
29 50.3 4.5 56.1 7.1
20 68.4 6.1 48.8 9.2
a The “WT”M3R corresponds to the full-length rat M3R containing an N-terminal
HA and a C-terminal EGFP tag.
TABLE 4
Characterization of mutant M3Rs containing Ala substitutions in the o2 loop in mammalian cells
All Ala substitutions were introduced into the ‘WT’M3R (full-length ratM3R containing anN-terminal HA and a C-terminal EGFP tag). The indicated receptor constructs
were transiently expressed in COS-7 cells and characterized in radioligand binding and functional studies, as described under “Experimental Procedures.” The Bmax value
calculated for the ‘WT’M3R was 4.2 0.7 pmol/mg protein, as determined in 3HNMS saturation binding studies. Carbachol-mediated increases in intracellular calcium
levels were measured via FLIPR (for details, see “Experimental Procedures”). Data are given as means S.E. of three independent experiments.
Receptor Ligand binding studies Functional studies
3HNMS Kd Carbachol Ki 3HNMS Bmax Carbachol EC50 Carbachol Emax
pM M % nM %
‘WT’ M3R 106 12 17.2 1.8 100 31.4 7.3 100
Q207A 90.3 7.8 17.0 2.8 78.2 11.3 245 24 102 5
R213A 114 6 34.7 6.1 69.5 9.4 608 22 79.5 6.6
E219A 125 14 25.1 4.2 76.6 7.3 37.1 8.1 101 4
I222A 175 14 72.7 6.5 82.5 8.0 312 19 89.2 5.2
Q223A 111 15 14.2 1.5 97.3 7.0 35.4 8.2 96.0 8.2
F224A 101 9 51.7 4.9 80.1 8.4 239 17 86.2 7.2
L225A 241 10 87.5 9.8 84.6 10.4 403 40 85.4 6.5
P228A 98.4 7.2 50.0 7.2 71.4 8.3 597 44 80.0 7.1
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pronounced reductions in carbachol potencies, ranging from8-
to 19-fold, as compared with the “WT” M3R (Table 4).
DISCUSSION
The high resolution x-ray structure of bovine rhodopsin sug-
gests that the extracellular regions of class I GPCRs are highly
structured (11). Interestingly, the rhodopsin structure clearly
indicates that the o2 loop folds down deeply into the TM recep-
tor core and that several o2 loop residues are in direct contact
with the cis-retinal ligand (11). A recent biochemical study car-
ried out with Cys-substituted mutant D2 dopamine receptors
suggests that the o2 loop of class I GPCRs that are activated by
biogenic amines or other small ligandsmay share similar struc-
tural properties (13). The proper spatial orientation of the o2
loop is maintained by a disulfide bond involving two Cys resi-
dues that are highly conserved among class I GPCRs (1, 2. 5, 11,
13). One of the two Cys residues is located in the center of the
o2 loop (corresponding to Cys220 in the M3R; Fig. 1), and the
other one is present at the extracellular end of TM III (corre-
sponding to Cys140 in Fig. 1). Site-directed mutagenesis studies
with many different class I GPCR subtypes, including theM3R,
have shown that this conserved disulfide bond is critical for
proper receptor folding and trafficking to the cell surface (see
Ref. 12 and references therein).
Besides the extensively studied conserved Cys residue, lit-
tle is known about the potential functional roles of other
amino acids located within the o2 loop. Previous studies
have demonstrated that biogenic amines and other small
ligands acting on class I GPCRs bind within the TM receptor
core by interacting with amino acids located on different TM
helices (7–10, 37). For this reason, the potential role of the
extracellular receptor domains in agonist-induced activa-
tion of class I GPCRs has not been studied systematically.
However, because residues in the o2 loop of rhodopsin and
biogenic amine receptors are predicted to be located in close
proximity of the classic ligand binding pocket (11, 13), it is
conceivable that o2 loop residues may play a role in stabiliz-
ing the agonist-induced receptor conformation that can pro-
ductively interact with G proteins.
To test this hypothesis, we initially employed a novel
experimental approach that involves receptor random
mutagenesis followed by a yeast genetic screen that can
recover mutant receptors containing single amino acid sub-
stitutions that disrupt receptor function in yeast (18). Using
this strategy, we previously identified a large number of sin-
gle point mutations that abolish M3R function in yeast (18).
These mutations were found throughout the M3R coding
sequence but occurred with particularly high frequency
within the TM receptor core (18). In this study, we used this
novel approach to identify mutant M3Rs containing point
mutations in the o2 loop and the N-term domain (see below)
that disrupt receptor function in yeast. The yeast screen per-
formed by Li et al. (18) was carried out under very stringent
conditions using a very high concentration of the muscarinic
agonist carbachol (10 mM). In this study, we reduced the
carbachol concentration to 1 mM, assuming that reducing
the stringency of the screen would lead to the recovery of
mutant receptors that had not been found previously. The
screen by Li et al. (18) identified only four inactivating point
mutations in the o2 loop (Q207L, C220S, C220R, and L225P),
all of which were also recovered in this study (Table 1).
In this study, M3R random mutagenesis was carried out
under conditions that favored the generation of mutant recep-
tors containing single amino acid substitutions. Consequently,
the receptor libraries that we generated did not contain all pos-
sible amino acid changes. However, as has been reviewed
recently (38), such libraries nevertheless retain a high level of
diversity because multiple amino acid substitutions can still
occur at each position.
Screening of the o2 loop library led to the identification of a
series of mutant receptors containing single amino acid substi-
tutions that abolishedM3R function in yeast (Table 1). Most of
these substitutions were recovered multiple times, indicating
that the yeast genetic screen was carried out at or near saturat-
ing conditions. The recovered point mutations involved the
following o2 loop residues: Gln207, Gly211, Arg213, Gly218,
Cys220, Ile222, Gln223, Phe224, Leu225, and Pro228. Residues
Arg213, Cys220, Gln223, and Phe224 were found to be substituted
by three or more different amino acids with diverse structural
properties (Table 1), suggesting that the side chains of these
four o2 loop residues are of particular importance for M3R
function.
To examine whether the point mutations recovered in the
yeast genetic screen also led to functional deficits in a mamma-
lian expression system, selected mutant receptors that were
inactive in yeast were studied in greater detail in transiently
transfected COS-7 cells (Table 2). To determine whether the
different amino acid substitutions interfered with agonist-de-
pendent G protein activation, we examined carbachol-medi-
ated increases in intracellular calcium levels using FLIPR tech-
nology. We found that all analyzed mutant receptors showed
pronounced (8–2,530-fold) reductions in carbachol potencies,
as compared with the “WT”M3R fromwhich all mutant recep-
tors were derived (Table 2). In contrast, with only few excep-
tions (see below), the majority of the analyzed o2 loop point
mutations had no or only minor effects on carbachol binding
affinities (Table 2). Most mutant receptors also displayed sig-
nificant reductions in receptor expression levels (Bmax) and car-
bachol efficacies (Emax; Table 2). To study the effects of reduced
Bmax levels on receptor function, we carried out calcium
release assays with cells expressing reduced levels of the
“WT” M3R (Table 3). This analysis strongly suggested that
the pronounced reduction in carbachol EC50 values dis-
played by all analyzed mutant receptors was not primarily a
consequence of reduced Bmax values but was most likely
because of mutation-induced impairments in agonist-in-
duced receptor activation.
Interestingly, two of the point mutations recovered in the
yeast genetic screen, G211W and G218V, involved the two gly-
cine residues present in the o2 loop of the M3R (Fig. 5).
Although the G211W and G218V mutant receptors showed
unchanged carbachol binding affinities (as compared with the
“WT” M3R), they showed a significant reduction (18- and
8-fold, respectively) in functional carbachol potencies (Table
2). Because glycine residues often function to increase the con-
formational flexibility of various protein domains (37), one pos-
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sibility is that the G211W and G218V mutations impaired
receptor function by restricting the conformational freedom of
the o2 loop required for efficient M3R activation. Consistent
with this concept, biophysical studies suggest that agonist acti-
vation of the serotonin 5-HT4(a) receptor involves a rearrange-
ment of the o2 loop (42).
Although all mutant M3Rs listed in Table 1 were inactive in
yeast, all analyzed mutant receptors retained considerable
activity in transfected COS-7 cells. One possible reason for this
phenomenon is that the yeast assay involved the monitoring of
yeast growth over a 2-day period, whereas the FLIPR assay used
for studying receptor activity inmammalian cellsmeasured flu-
orescence (calcium) responses that reached maxima within
several seconds. Moreover, although the mutant M3Rs were
forced to interact with a yeast/mammalian hybrid Gpa1p/q G
protein in yeast, they were able to couple to native Gq-type G
proteins in transfected mammalian cells. Finally, radioligand
binding studies have shown thatM3Rs are expressed at consid-
erably higher levels (
10-fold) in transfected COS-7 cells than
in the MPY578q5 yeast strain (27).
To examine towhich extent the newly introduced amino acid
side chains contributed to the functional impairment displayed
by the mutant M3Rs listed in Table 2, selected o2 loop residues
were also subjected to Ala substitution mutagenesis (Table 4).
In general, the resulting mutant receptors showed only rela-
tively small or no significant reductions inBmax andEmax values.
However, with only two exceptions, E219A andQ223A, all ana-
lyzed Ala mutant receptors (Q207A, R213A, I222A, F224A,
L225A, and P228A) showed pronounced reductions (8–19-
fold) in carbachol potencies, as compared with the “WT” M3R
(Table 4; Fig. 4). These latter six mutant M3Rs showed either
unchanged or only rather small reductions (2–5-fold) in car-
bachol binding affinities (Table 4), strongly suggesting that the
targeted amino acids are of particular functional importance by
enabling carbachol to activate the M3R with high efficiency
(potency). The R213A and P228A constructs showed the most
pronounced reductions in carbachol potencies (19-fold), sug-
gesting that Arg213 and Pro228 play key roles in agonist-induced
M3R activation.
The ligand binding and functional properties of the Q223A
mutant receptorwere indistinguishable from those of the “WT”
M3R (Table 4), suggesting that Gln223 does not play a critical
role in M3R function. In contrast, the Q223K mutant receptor
showed a pronounced reduction (28-fold) in carbachol potency
(Table 2). These observations suggest that the functional
impairment displayed by the Q223Kmutant receptor wasmost
likely because of detrimental structural effects caused by the
newly introduced Lys side chain.
Glu219 is the only negatively charged residue present in the
o2 loop of the M3R (Fig. 5). Moreover, this residue is situated
directly adjacent to Cys220, suggesting that Glu219 is located
inside the TM receptor core (11). Based on these observations,
we also analyzed the E219Amutant M3R in transfected COS-7
cells. However, we found that the ligand binding and functional
properties of the E219A mutant receptor were similar to those
of the “WT” M3R (Table 4), indicating that the presence of
Glu219 is not required for efficient M3R function. In agreement
with this notion, the yeast genetic screen did not lead to the
recovery of any mutant M3Rs containing amino acid substitu-
tions at position Glu219.
Fig. 5 shows that the o2 loop residues that are required for
efficient agonist-mediated M3R activation (Gln207, Gly211,
Arg213, Gly218, Cys220, Ile222, Phe224, Leu225, and Pro228) are
scattered throughout the o2 loop sequence. Interestingly, most
of these residues (Gln207, Gly211, Arg213, Cys220, Ile222, and
Phe224) are conserved among all five muscarinic receptor sub-
types (Fig. 5), further highlighting the potential structural
and/or functional importance of these residues.
We recently established a three-dimensional model of the
inactive state of the M3R, based on homology modeling using
the high resolution x-ray structure of bovine rhodopsin as a
template (11, 48). Fig. 6 indicates that the functionally critical
o2 loop residues identified in this study are located within dif-
ferent o2 loop subdomains (Gln207,
beginning of the o2 loop close to
TM IV; Gly211, 3 strand; Arg213
and Gly218, hinge region connecting
the 3 and 4 strands; Cys220, 4
strand; Ile222, Phe224, Leu225, and
Pro228, C-terminal segment of the
o2 loop).
In a related study, Klco et al. (26)
subjected the o2 loop of the C5a
receptor, another class I GPCR, to
random mutagenesis and used a
FIGURE 4. Functional characterization in COS-7 cells of mutant M3Rs in
which specific o2 loop residues were replaced with Ala. All Ala substitu-
tions were introduced into the “WT” M3R. The resulting receptor constructs
were transiently expressed in COS-7 cells. Carbachol-induced increases in
intracellular calcium levels were measured via FLIPR (for details, see “Experi-
mental Procedures”). Fluorescence counts are given in arbitrary units. The
curves shown are representative of three independent experiments. Date are
given as means S.D. Assays were carried in quadruplicate. Carbachol EC50
and Emax values are listed in Table 4.
FIGURE 5. Comparison of the o2 loop sequences of the five human muscarinic receptor subtypes (M1–
M5).Numbers indicateM3R residues (top row) whose presence is required for efficient carbachol-inducedM3R
activation. Amino acid numbers refer to positions in the rat M3R sequence (46). Note that the rat and human
M3Rs have identical sequences in the region displayed here. The asterisks indicate positions where all five
muscarinic receptor subtypes have identical amino acids. Sequences were taken from Ref. 8.
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yeast genetic screen to recover mutant receptors that retained
functional activity. Interestingly, the authors identified a series
of mutant C5a receptors containing multiple point mutations
in the o2 loop that were able to activate G proteins even in the
absence of ligands. These findings led to the proposal that spe-
cific o2 loop residues establish contacts with the TM receptor
core, thus stabilizing the inactive state of the receptor (26).
However, by using randommutagenesis of the entireM3R cod-
ing sequence, followed by yeast genetic screens, we have been
unable to identify activating point mutations in the o2 loop of
theM3R.4 Similarly, previous randommutagenesis studies car-
ried out with the angiotensin II type 1A (39) and the -opioid
(40) receptors failed to identify point mutations in the o2 loop
that rendered these receptors constitutively active.
In contrast to the model proposed by Klco et al. (26), the
results of this study rather suggest that specific o2 loop residues
are required for efficient agonist-induced M3R activation. We
found that amino acid substitutions at several specific sites
within the o2 loop had pronounced effects on functional carba-
chol potencies but only minor effects on carbachol binding
affinities. Therefore, one likely scenario is that the side chains of
the mutated amino acids are involved in interactions that sta-
bilize the active state of the M3R that can productively interact
withGproteins. This concept is in agreementwith the outcome
of a previous study demonstrating that several o2 loop residues
determine whether ATP functions as an agonist or an antago-
nist at mammalian P2Y4 receptors (41). Moreover, Baneres et
al. (42) recently provided direct biophysical evidence that ago-
nist binding to the serotonin 5-HT4(a) receptor is associated
with a rearrangement of the o2 loop.
In contrast to the results that we obtained with the o2 loop
library, our yeast genetic screen failed to recover any single
inactivating point mutations located within the N-term region
of the M3R (Thr2–Gln66). Transient expression of a mutant
M3R lacking Thr2–His62 led to an90% reduction in receptor
expression levels (Bmax), as compared with the “WT” M3R
(Table 2). When the “WT”M3R was expressed at similarly low
levels, carbachol was able to activate the two receptors with
similar potencies and efficacies. These observations indicate
that the N-term region of the M3R most likely plays a role in
M3R stability and/or cell surface trafficking but does not con-
tain structural elements that determine the efficiency of ago-
nist-induced receptor activation. It is likely that this domain has
a similar function in other class I GPCRs.
In the yeast genetic screen, we identifiedmanymutantM3Rs
that contained multiple point mutations within the N-term
region. Therefore, one possibility is that thesemutantM3Rs are
functionally inactive in yeast because of reduced stability
and/or impaired cell surface trafficking.
In conclusion, we used receptor random mutagenesis and a
novel yeast genetic screen to identify inactivating point muta-
tions located in the o2 loop of the M3R. Pharmacological char-
acterization of many of the recovered mutant M3Rs in mam-
malian cells, complemented by site-directed mutagenesis
studies, strongly suggested that the presence of several o2 loop
residues is important for efficient agonist-inducedM3R activa-
tion. Because mutational modification of these residues had
little effect on agonist binding affinities, a likely scenario is that
these residues stabilize the active state of the M3R.
To the best of our knowledge, this study represents the most
comprehensive analysis of the functional role of the o2 loop of a
class I GPCR activated by a small diffusible ligand. The
approach described here should be applicable to all GPCRs that
can be expressed in yeast in a functional form (43–45).
4 B. Li, C. Schmidt, and J. Wess, unpublished results.
FIGURE6.Modelof the inactivestateof theM3Rhighlighting functionally
critical amino acids in the o2 loop. A, side view. B, extracellular view. The
M3R model was established via homology modeling based on the crystal
structure of the resting state of bovine rhodopsin (11, 48). The o2 loop
(magenta) is predicted to fold deeply into the center of the receptor core. The
second and third extracellular loops (o1 and o3, respectively), which are dis-
played as white-gray bands, are short and run along the periphery of the
receptor. The extracellular N-terminal domain is not shown for the sake of
clarity. Amino acids located in the o2 loop of the M3R whose presence is
required for efficient carbachol-inducedM3Ractivation arehighlighted in red
(C- atoms). The white molecule present at the center of the receptor in A
represents the endogenous ligand, acetylcholine, docked into its binding site
within the TM receptor core. Amino acid numbers refer to positions in the
full-length rat M3R sequence (46).
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